# CRENESSITY
> **NDA218808** · New Drug Application · Sponsor: NEUROCRINE · Approved 2024-12-13
## Drug
- **FDA Application Number:** NDA218808
- **Application type:** New Drug Application
- **Brand name:** CRENESSITY
- **Generic name:** CRINECERFONT
- **Active ingredients:** CRINECERFONT
- **Dosage form:** CAPSULE
- **Route:** ORAL
- **Marketing status:** Prescription
- **Sponsor:** NEUROCRINE
- **Manufacturer:** Neurocrine Biosciences, Inc.
- **First approval:** 2024-12-13
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218808)
---
*AI Analytics · CC0 1.0*